By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Immunization. According to news originating from Durham, North Carolina, by NewsRx correspondents, research stated, "First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising platforms for use as cancer vaccines, are impeded in activity by naturally occurring or induced Ad-specific neutralizing antibodies. Ad5-based vectors with deletions of the E1 and the E2b regions (Ad5 [E1-, E2b-]), the latter encoding the DNA polymerase and the pre-terminal protein, by virtue of diminished late phase viral protein expression, were hypothesized to avoid immunological clearance and induce more potent immune responses against the encoded tumor antigen transgene in Ad-immune hosts."
Our news journalists obtained a quote from the research from Duke University Medical Center, "Indeed, multiple homologous immunizations with Ad5 [E1-, E2b-]-CEA(6D), encoding the tumor antigen carcinoembryonic antigen (CEA), induced CEA-specific cell-mediated immune (CMI) responses with antitumor activity in mice despite the presence of preexisting or induced Ad5-neutralizing antibody. In the present phase I/II study, cohorts of patients with advanced colorectal cancer were immunized with escalating doses of Ad5 [E1-, E2b-]-CEA(6D). CEA-specific CMI responses were observed despite the presence of preexisting Ad5 immunity in a majority (61.3 %) of patients. Importantly, there was minimal toxicity, and overall patient survival (48 % at 12 months) was similar regardless of preexisting Ad5 neutralizing antibody titers."
According to the news editors, the research concluded: "The results demonstrate that, in cancer patients, the novel Ad5 [E1-, E2b-] gene delivery platform generates significant CMI responses to the tumor antigen CEA in the setting of both naturally acquired and immunization-induced Ad5-specific immunity."
For more information on this research see: Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2013;62(8):1293-301. (Springer - www.springer.com; Cancer Immunology, Immunotherapy - www.springerlink.com/content/0340-7004/)
The news correspondents report that additional information may be obtained from M.A. Morse, Dept. of Medicine, Duke University Medical Center, Durham, NC 27710, United States. Additional authors for this research include A. Chaudhry, E.S. Gabitzsch, A.C. Hobeika, T. Osada, T.M. Clay, A. Amalfitano, B.K. Burnett, G.R. Devi, D.S. Hsu, Y. Xu, S. Balcaitis, R. Dua, S. Nguyen, J.P. Balint, F.R. Jones and H.K Lyerly (see also Immunization).
Keywords for this news article include: Antibodies, Biotechnology, Durham, Oncology, Colorectal, Immunology, Colon Cancer, Immunization, United States, North Carolina, Bioengineering, Blood Proteins, Cancer Vaccines, Immunoglobulins, Gastroenterology, Cancer Gene Therapy, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC